Evaluation of safety of bioactive concentrate of small marine fish in senile patients with knee osteoarthritis and high comorbidity rates
- Authors: Malyshenko O.S.1, Taskina E.A.2, Raskina T.A.1, Averkieva Y.V.1, Usova E.V.1, Koroleva M.V.1, Letaeva M.V.1
-
Affiliations:
- Kemerovo State Medical University of the Ministry of Healthcare of Russia
- V.A. Nasonova Scientific Research Institute of Rheumatology
- Issue: Vol 9, No 3 (2023)
- Pages: 148-155
- Section: ACTUAL ISSUES OF PHARMACOTHERAPY AND PREVENTIVE TREATMENT
- URL: https://journals.eco-vector.com/2412-4036/article/view/516481
- DOI: https://doi.org/10.18565/therapy.2023.3.148–155
- ID: 516481
Cite item
Open Access
Access granted
Abstract
Nowadays osteoarthritis (OA) is the most common disease and a major cause of pain and disability in elderly and senile patients. Irrational therapy of OA on the basis of comorbidity leads to increase in the number of adverse events and aggravation of the course of concomitant diseases.
Aims of the research: main is to evaluate the safety of a bioactive concentrate of small marine fish (BCSMF) in senile patients with knee osteoarthritis and high comorbidity; additional one – to evaluate the effectiveness of therapy during the observation period.
Material and methods. 20 patients with OA of the knee joint, whose mean age was 77,6 (75,8; 80,5) years old were involved in the study. They received injections of BCSMF daily, 1 ml intramuscularly, in courses of 20 days with a 6-month interval (2 courses in total). The effectiveness of therapy was assessed by VAS and the WOMAC index, the safety of the drug was assessed based on clinical and laboratory parameters throughout the total observation period.
Results. Elderly patients with OA of knee joint showed a high level of comorbidity – about 5,4+0,8 diseases. By the end of the first course of therapy with BCSMF, a statistically significant decrease in the total WOMAC index and a significant decrease in pain according to VAS were found. Positive dynamics preserved throughout the total observation period. Serious adverse events and clinically significant changes in laboratory parameters were not detected during the total period of observation.
Conclusion. The results of the study demonstrate the effectiveness of BCSMF in patients with knee joint OA and confirm the safety of its use in senile patients with high comorbidity, which allows it to be considered as a first-line drug in the complex treatment of OA.
Full Text
About the authors
Olga S. Malyshenko
Kemerovo State Medical University of the Ministry of Healthcare of Russia
Author for correspondence.
Email: malyshenko.mos@yandex.ru
ORCID iD: 0000-0001-8272-3736
PhD in Medical Sciences, Associate Professor of the Department of Propaedeutics of Internal Diseases
Russian Federation, KemerovoElena A. Taskina
V.A. Nasonova Scientific Research Institute of Rheumatology
Email: braell@mail.ru
ORCID iD: 0000-0001-8218-3223
PhD in Medical Sciences, Senior Researcher of the Department of Metabolic Diseases of Bones and Joints
Russian Federation, MoscowTatyana A. Raskina
Kemerovo State Medical University of the Ministry of Healthcare of Russia
Email: rassib@mail.ru
ORCID iD: 0000-0002-5804-4298
MD, Professor, Head of the Department of Propaedeutics of Internal Diseases
Russian Federation, KemerovoYulia V. Averkieva
Kemerovo State Medical University of the Ministry of Healthcare of Russia
Email: doctor-averkieva@yandex.ru
ORCID iD: 0000-0001-8020-4545
PhD in Medical Sciences, Assistant at the Department of Propaedeutics of Internal Diseases
Russian Federation, KemerovoEkaterina V. Usova
Kemerovo State Medical University of the Ministry of Healthcare of Russia
Email: usova.ekaterina.93@mail.ru
ORCID iD: 0000-0002-2988-1652
Postgraduate Student of the Department of Propaedeutics of Internal Diseases
Russian Federation, KemerovoMarina V. Koroleva
Kemerovo State Medical University of the Ministry of Healthcare of Russia
Email: 576078@mail.ru
ORCID iD: 0000-0002-0184-7997
PhD in Medical Sciences, Assistant at the Department of Propaedeutics of Internal Diseases
Russian Federation, KemerovoMarina V. Letaeva
Kemerovo State Medical University of the Ministry of Healthcare of Russia
Email: letaeva@yandex.ru
ORCID iD: 0000-0003-3907-7120
PhD in Medical Sciences, Associate Professor of the Department of Propaedeutics of Internal Diseases
Russian Federation, KemerovoReferences
- Cleveland R.J., Nelson A.E., Callahan L.F. Knee and hip osteoarthritis as predictors of premature death: a review of the evidence. Clin Exp Rheumatol. 2019; 37 Suppl 120(5): 24–30.
- Wilkie R., Parmar S.S., Blagojevic-Bucknall M. et al. Reasons why osteoarthritis predicts mortality: path analysis within a cox proportional hazards model. RMD. 2019; 5(2): e001048. http://dx.doi.org/10.1136/rmdopen-2019-00104.
- Hawker G.A. Osteoarthritis is a serious disease. Clin Exp Rheumatol. 2019; 37 Suppl 120(5): 3–6.
- Swain S., Sarmanova A., Coupland C. et al. Comorbidities in osteoarthritis: a systematic review and meta-analysis of observational studies. Arthritis Care Res. 2020; 72(7): 991–1000. http://dx.doi.org/10.1002/acr.24008.
- Betancourt M., Marachi E., Machado E., de Azevedo e Souza Munhoz M. Detection of possible problematic polypharmacy in patients with osteoarthritis and associated factors. Osteoarthr Cartil. 2022; 30: 195–96. http://dx.doi.org/10.1016/j.joca.2022.02.262.
- Каратеев А.Е., Насонов Е.Л., Ивашкин В.Т. с соавт. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018; 56(S1): 1–29. [Karateev A.E., Nasonov E.L., Ivashkin V.T. et al. Rational use of nonsteroidal antiinflammatory drugs. Clinical guidelines. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2018; 56(S1): 1–29 (In Russ.)]. http://dx.doi.org/10.14412/1996-7012-2015-1-4-23. EDN: PCPKRP.
- Walckiers D., Van der Heyden J., Tafforeau J. Factors associated with excessive polypharmacy in older people. Arch Public Health. 2015; 73: 50. https://dx.doi.org/10.1186/s13690-015-0095-7.
- Bruyere O., Honvo G., Veronese N. et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019; 49(3): 337–50. https://dx.doi.org/10.1016/j.semarthrit.
- Клинические рекомендации. Остеоартроз. Общероссийская общественная организация «Ассоциация ревматологов России». 2016. Доступ: https://medi.ru/klinicheskie-rekomendatsii/osteoartroz_14116/ (дата обращения – 01.04.2023). [Clinical guidelines. Osteoarthrosis. Association of Rheumatologists of Russia (In Russ.)]. URL: https://medi.ru/klinicheskie-rekomendatsii/osteoartroz_14116/ (date of access – 01.04.2023) (In Russ.)].
- Шостак Н.А., Правдюк Н.Г., Клименко А.А. с соавт. Остеоартрит и ассоциированная патология – клинико-патогенетические взаимосвязи. РМЖ. Медицинское обозрение. 2019; 3(11–2): 44–47. [Shostak N.A., Pravdyuk N.G., Klimenko A.A. et al. Osteoarthritis and associated pathology-clinical and pathogenetic associations. Russkiy meditsinskiy zhurnal. Meditsinskoye obozreniye = Russian Medical Journal. Medical Review. 2019; 3(11–2): 44–47 (In Russ.)]. EDN: UEDLQN.
- Шарапова Е.П., Алексеева Л.И., Таскина Е.А. с соавт. Многоцентровое проспективное рандомизированное исследование эффективности и безопасности препарата Алфлутоп в альтернирующем режиме по сравнению со стандартным режимом. Сообщение 2: оценка безопасности препарата при различных схемах применения. Современная ревматология. 2020; 14(1): 67–73. [Sharapova E.P., Alekseeva L.I., Taskina E.A., et al. A multicenter, prospective, randomized trial of the efficacy and safety of Alflutop® in an alternating dosing regimen versus the standard one. Communication 2: Evaluation of the efficacy of the drug in different use regimens. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2020; 14(1): 67–73 (In Russ.)]. https://dx.doi.org/10.14412/1996-7012-2020-1-67-73. EDN: DNDPJB.
- Алексеева Л.И., Таскина Е.А., Лила А.М. с соавт. Многоцентровое проспективное рандомизированное исследование эффективности и безопасности препарата Алфлутоп в альтернирующем режиме по сравнению со стандартным режимом. Сообщение 1: оценка эффективности препарата при различных схемах применения. Современная ревматология. 2019; 13(3): 51–59. [Alekseeva L.I., Taskina E.A., Lila A.M. et al. A multicenter, prospective, randomized trial of the efficacy and safety of Alflutop® in an alternating dosing regimen versus the standard one. Communication 1: Evaluation of the efficacy of the drug in different treatment regimens. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2019; 13(3): 51–59 (In Russ.)]. https://dx.doi.org/10.14412/1996-7012-2019-3-51-59. EDN: YXZKNO
- Пешехонова Л.К., Красюков П.А., Пешехонов Д.В. Оценка роли Алфлутопа в терапии остеоартроза: показания, клиническая эффективность, переносимость и влияние на качество жизни. Медицинский совет. 2016; (11): 100–104. [Peshekhonova L.K., Krasyukov P.A., Peshekhonov D.V. Evaluation of the role of Аlflutop in the osteoarthritis treatment: Indications, clinical efficacy, tolerability and impact on quality of life. Meditsinskiy sovet = Medical Council. 2016; (11): 100–104 (In Russ.)]. https://dx.doi.org/10.21518/2079-701X-2016-11-100-104. EDN: XDGGZB.
- Воронина Н.В., Слуцкая Н.П., Маркина О.И. с соавт. Особенности лечения остеоартроза коленных суставов у больных оксалатной нефропатией. Терапевтический архив. 2015; 87(4): 62–68. [Voronina N.V., Slutskaya N.P., Markina O.I. et al. Treatment for knee osteoarthritis in patients with oxalate nephropathy. Terapevticheskiy arkhiv = Therapeutic Archive. 2015; 87(4): 62–68 (In Russ.)]. https://dx.doi.org/10.17116/terarkh201587462-68. EDN: QIPFKP.
- Каратеев А.Е. Биоактивный концентрат мелкой морской рыбы: оценка эффективности и безопасности препарата на основании анализа 37 клинических исследований. Современная ревматология. 2020; 14(4): 111–124. [Karateev A.E. Bioactive concentrate from small sea fish: Evaluation of the efficacy and safety of the drug on the basis of the analysis of 37 clinical trials. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2020; 14(4): 111–124 (In Russ.)]. https://dx.doi.org/10.14412/1996-7012-2020-4-111-124. EDN: JEPCAS.
Supplementary files
